CENTER FOR NEUROLOGIC STUDY

The center for neurologic study is a leader in translational medicine. The approval of qalsody for the treatment of the sod1 familial variant of als is a recent example, leading to a healey prize for the director's drug discovery efforts and leading to the publication of neurotherapeutics in the era of translational medicine. The seminal discovery of dmq at cns, ultimately formulated by avanir pharmaceuticals corporation as nuedexta, was approved by fda in 2010 for the treatment of emotionality that occurs with numerous neurological disorders. Its therapeutic effect on speech and swallowing was recently published in neurotherapeutics, the first therapy to enhance any function in this disease. The study was funded by the als association. This year the european journal of neurology published the center's finding of a self-replicating protein in the spinal fluid of approximately fifteen percent of als patients. This surprising result could lead to a breakthrough treatment.